Clinical Snippets
June 2004
in “
Journal of Investigative Dermatology
”
stem cell factor UVB irradiation intradermal nociceptin hair follicle melanocytes β-endorphin melanogenesis sunscreen ingredients reproductive hormone levels environmental estrogens TNF-α inhibitor chemotactic peptide agonists H1 receptor antagonists chemotherapy-induced hair loss SCF UVB nociceptin melanocytes endorphin sunscreen hormone levels estrogens TNF inhibitor peptide agonists antihistamines chemo hair loss
TLDR Increased pigmentation may protect skin from UVB, new targets for skin disease treatments were identified, sunscreen ingredients don't affect hormones, TNF-α inhibitors may help diabetic wounds, and certain treatments could prevent chemotherapy-induced hair loss.
The document presented several studies related to dermatology. In one study, XP knockout mice with increased stem cell factor (SCF) showed that increased pigmentation protected against UVB irradiation, suggesting potential for skin protection strategies. Another study found that intradermal nociceptin induced itching in mice, highlighting new therapeutic targets for skin diseases. Research on hair follicle melanocytes revealed that β-endorphin upregulated melanogenesis, though opiate effects may limit research. Sunscreen ingredients were found in blood and urine, but did not alter reproductive hormone levels, reducing concerns about environmental estrogens. Diabetic mice with skin infections showed prolonged inflammation, which was reduced by a TNF-α inhibitor, suggesting potential treatments for diabetic wounds. Lastly, chemotactic peptide agonists and H1 receptor antagonists prevented chemotherapy-induced hair loss in rats, offering hope for similar treatments in humans.
